Identification and experimental validation of CD74, PGLYRP1, and TXN as potential biomarkers in rheumatoid arthritis: an integrative bulk and ScRNA-seq study - Report - MDSpire
Advertisement
Identification and experimental validation of CD74, PGLYRP1, and TXN as potential biomarkers in rheumatoid arthritis: an integrative bulk and ScRNA-seq study
Clinical Report: Discovery and experimental confirmation of CD74, PGLYRP1, and TXN as promising biomarkers for rheumatoid arthritis
Overview
This study identifies CD74, PGLYRP1, and TXN as potential biomarkers for rheumatoid arthritis (RA) through a comprehensive analysis of transcriptomic datasets and validation in clinical samples.
Background
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and damage, with a significant impact on patient quality of life. Current biomarkers for RA diagnosis and prediction have limitations in specificity and sensitivity, necessitating the discovery of new biomarkers.
Data Highlights
No numerical data available.
Key Findings
CD74, PGLYRP1, and TXN were identified as potential biomarkers for RA.
CD74 expression was significantly downregulated, while PGLYRP1 and TXN were upregulated in RA clinical samples compared to controls.
CD56dim natural killer cells showed a positive correlation with CD74 and a negative correlation with TXN.
Machine learning algorithms and expression validation were utilized to identify these biomarkers.
Single-cell RNA sequencing indicated myeloid cells as a key population in RA.
Clinical Implications
The identification of CD74, PGLYRP1, and TXN as biomarkers may assist in RA diagnosis.
Conclusion
The study integrates bulk RNA sequencing with single-cell RNA sequencing to identify biomarkers for RA.
